Arcutis Biotherapeutics Inc (ARQT) - Total Liabilities
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has total liabilities worth $270.36 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Arcutis Biotherapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Arcutis Biotherapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Arcutis Biotherapeutics Inc (ARQT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Arcutis Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-A
|
Sweden | Skr168.96 Billion |
|
Chunghwa Precision Test Tech Co Ltd
TWO:6510
|
Taiwan | NT$1.17 Billion |
|
Adani Wilmar Limited
NSE:AWL
|
India | Rs143.15 Billion |
|
Rocket Internet SE
HM:RKET
|
Germany | €243.60 Million |
|
Digital China Group Co Ltd
SHE:000034
|
China | CN¥44.03 Billion |
|
EO Technics Co. Ltd
KQ:039030
|
Korea | ₩96.55 Billion |
|
Acer Incorporated
F:AC5G
|
Germany | €147.16 Billion |
|
Altarea SCA
PA:ALTA
|
France | €4.88 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Arcutis Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARQT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcutis Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Arcutis Biotherapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $243.49 Million | +27.25% |
| 2024-12-31 | $191.35 Million | -24.28% |
| 2023-12-31 | $252.70 Million | +5.43% |
| 2022-12-31 | $239.69 Million | +116.97% |
| 2021-12-31 | $110.47 Million | +299.58% |
| 2020-12-31 | $27.65 Million | +398.16% |
| 2019-12-31 | $5.55 Million | -92.61% |
| 2018-12-31 | $75.08 Million | +752.08% |
| 2017-12-31 | $8.81 Million | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more